UPDATE: Roth Capital Starts Monopar Therapeutics (MNPR) at Buy

Roth Capital analyst Elemer Piros initiates coverage on Monopar Therapeutics (NASDAQ: MNPR) with a Buy rating and a price target of $49.00.

The analyst comments "There are no drugs approved for SOM, a debilitating consequence of chemoradiotherapy of oral cancer. With a recently failed pivotal trial, Monopar and Galera are the only two companies with programs in advanced clinical trials. In Phase 2 trials, both Monopar's Validive and Galera's GC4419 were similarly efficacious in reducing the incidence, time-to-onset and duration of SOM. The clear advantage to Validive is the once daily pill formulation, as opposed to the daily weekday IV administration of GC4419 for seven weeks. All else being equal, we believe that Validive could capture the lion's share of the market."

For an analyst ratings summary and ratings history on Monopar Therapeutics click here. For more ratings news on Monopar Therapeutics click here.

Shares of Monopar Therapeutics closed at $6.60 yesterday.

You May Also Be Interested In

• Chr Hansen Holding A/S (CHR:DC) (CHYHY) PT Lowered to DKK610 at UBS
• 1&1 Drillisch AG (DRI:GR) PT Raised to EUR24 at Goldman Sachs
• Champion Iron Ltd. (CIA:CN) (CHPRF) PT Raised to Cdn$6 at Canaccord Genuity